What to know about Elevation Oncology Inc (ELEV)’s sales and margins

Elevation Oncology Inc [ELEV] stock prices are up 2.81% to $5.13 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ELEV shares have gain 12.01% over the last week, with a monthly amount glided 2.40%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

On 6, March 2024, Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements. In a post published today on Yahoo Finance, –Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 —- Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual Meeting; plan to nominate development candidate in 2024 –– Raised approximately $17.0M in net proceeds through at-the-market (ATM) facility and refinanced debt facility with K2 Health Ventures; cash runway into the fourth quarter of 2025 –.

From an analyst’s perspective:

Elevation Oncology Inc [NASDAQ: ELEV] stock has seen the most recent analyst activity on March 01, 2024, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $7. Previously, SVB Securities upgraded its rating to Outperform on May 30, 2023, and elevated its price target to $8. On December 23, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $12 on the stock.

The stock price of Elevation Oncology Inc [ELEV] has been fluctuating between $0.36 and $5.89 over the past year. Elevation Oncology Inc [NASDAQ: ELEV] shares were valued at $5.13 at the most recent close of the market.

Analyzing the ELEV fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.82 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.55.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.94 points at the first support level, and at 4.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.27, and for the 2nd resistance point, it is at 5.40.

Elevation Oncology Inc [ELEV] reported earnings per share of -$0.19 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.24/share, meaning a difference of $0.05 and a surprise factor of 20.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.25 per share as compared to estimates of -$0.32 per share, a difference of $0.07 representing a surprise of 21.90%.

Ratios To Look Out For

It’s worth pointing out that Elevation Oncology Inc [NASDAQ:ELEV]’s Current Ratio is 21.22. Also, the Quick Ratio is 21.22, while the Cash Ratio stands at 11.88.

Related Posts